GLI1 and acute promyelocytic leukemia: Yang et al. demonstrated that ATO therapy in APL patients leads to compete remission in 86% of cases, and these patients show a significant downregulation of GLI2 and SMO gene expression, and marginal downregulation of PTCH1 and GLI1 [254].